Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving (177)Lu-PSMA-617 Radioligand Therapy

Rationale: Lu-177-PSMA-617 radioligand therapy (RLT) is currently under approval for treatment of metastatic castration resistant prostate cancer (mCRPC) patients with late stage disease. However, previous studies demonstrated both heterogeneity of prostate specific membrane antigen (PSMA) expressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Kessel, Katharina, Seifert, Robert, Weckesser, Matthias, Roll, Wolfgang, Humberg, Verena, Schlack, Katrin, Bögemann, Martin, Bernemann, Christof, Rahbar, Kambiz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359074/
https://www.ncbi.nlm.nih.gov/pubmed/32685010
http://dx.doi.org/10.7150/thno.44556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359074/
https://www.ncbi.nlm.nih.gov/pubmed/32685010
http://dx.doi.org/10.7150/thno.44556

Ejemplares similares